PAVmed Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Charles Duncan - Cantor Fitzgerald - Analyst : Yes, absolutely. No worries, Dennis. You did a great job running through the PAVmed story, and I appreciate it. I do have some questions on the non-Lucid side of the business, which I think is perhaps intriguing. Before we go there, why don't I just ask you a quick question on Lucid. It does seem like EsoGuard and EsoCheck results in an interesting pharmacoeconomic model. So it seems like there's both a read-in as well as a read-out value in terms of a more costly interventional procedure. Is that your perspective as well?

Question: Charles Duncan - Cantor Fitzgerald - Analyst : So happy example, doing well by doing good for patients, prescribers, or interventionalists, as well as reimbursement parties.

Question: Charles Duncan - Cantor Fitzgerald - Analyst : Absolutely interesting use of technology to change the paradigm for therapy, for treatment, for diagnosis. Appreciate you spending the time to explain the PAVmed story for us, Dennis. Unfortunately, we are out of time.

Question: Charles Duncan - Cantor Fitzgerald - Analyst : Absolutely. Thank you.